Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty

Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty

IntroductionOvarian cancer (OVCA) has a five-year survival rate of approximately 45%, with little improvement over recent decades. Although anti-PD-L1 therapies have shown substantial efficacy in other solid tumors, their effectiveness in OVCA has been limited. These treatments target only membranou...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Meshach Asare-Werehene, Arvin Zaker, Shivanshi Tripathi, Laudine Communal, Euridice Carmona, Anne-Marie Mes-Masson, Benjamin K. Tsang, Arvind Mer
Natura: Articolo
Lingua:inglese
Pubblicazione: Frontiers Media S.A. 2025-07-01
Serie:Frontiers in Immunology
Soggetti:
PD-L1
immunotherapy
nuclear PD-L1
ovarian cancer
chemoresistance
tumor microenvironment
Accesso online:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1543529/full
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
Lascia un commento!
Entra

Documenti analoghi